Speakers: Andreas Schmidt, PhD, CEO, Proteona and Jonathan Scolnick, PhD, Assistant Professor, National University of Singapore & Co-founder, Proteona
Title:
Using single cell proteogenomics to improve therapies: from cancer to infectious disease
Abstract:
Cancer is the second leading cause of death in the world, and while phenomenal progress has been made in identifying new therapeutics, considerable work must still be done to determine which patients will benefit most from each of those drugs. Five years ago, our group began to develop tools for dissecting tumors at the single cell level in order to determine how to best treat each cell. The emergence of COVID-19 threatened to decimate the very groups of patients we work with, including those with blood cancers who are immunocompromised. However, we quickly realized that the same tools we use to improve cancer treatments could be used to identify neutralizing antibodies against the SARS-CoV-2 virus and shifted the focus of our work. In this webinar, we will tell two stories of how we are using our Enhanced Single Cell Analysis with Protein Expression (ESCAPE™) RNA sequencing assay and MapCell AI™ with the 10x Genomics single cell analysis platform to tackle a diversity of problems in both cancer and infectious disease.
In this webinar, you will learn:
- The importance of including proteogenomics in your single cell analysis.
- How automated cell annotation using MapCell AI can improve consistency and quality of your analysis workflow.
- How to identify antibodies against infectious diseases using single cell analysis, with SARS-CoV-2 as an example.
Speaker: Cristina Baricordi, PhD, Scientist, AVROBIO
Title:
A single cell RNA analytical platform for characterizing cell states in gene therapy drug products
Abstract:
Human hematopoietic/stem progenitor (HSPC) CD34+ cells are the core components of ex vivo gene therapy (GT) for the treatment of rare monogenic diseases. Assessment of CD34+ cells for their long-term hematopoietic stem cell (HSC) content before and after ex vivo transduction, as well as in vivo after transplantation, is a critical parameter to establish the efficacy of GT. To overcome the limitations of standard immunophenotyping, we leveraged the high resolution offered by single cell (sc)-RNA-sequencing to capture the heterogeneity of HSPC states and its dynamic changes. Through integrated analysis of the scRNA of individually cultured HSPC subsets and bulk CD34+ before and after in vitro manipulation (total of 176,250 single cells), we unveiled the impact of cell culture conditions on the composition of the GT drug product. We anticipate such information will allow us to generate a robust protocol for the manufacture of transduced CD34+ cells for HSPC GT.
In this webinar, you will learn:
- The composition of the human HSPC compartment and current methods for its characterization.
- The main therapeutic applications of HSPCs for human gene therapy.
- How scRNA-seq allows high-resolution capture of HSPC heterogeneity in different cell sources.
- How scRNA-seq can be applied to comprehensively characterize the gene therapy drug product.
